# US 2024/0002810 A1 · Cell-derived particles presenting heterologous cd24 and use thereof in therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002810 A1
- Document ID: US20240002810A1
- Status: Published application
- Kind: A1
- Application number: 18/224,131
- Filed: 2023-07-20
- Published: 2024-01-04
- Earliest claimed: 2020-04-16
- Assignees: Ichilov Tech Ltd.
- Applicants: Ichilov Tech Ltd.
- Inventors: Nadir ARBER; Shiran SHAPIRA
- Web page: https://patentgrep.com/patent/US20240002810A1

## CPC

- A61K 35/33: Fibroblasts
- C12N 5/0686: {Kidney cells}
- A61K 9/5068: {Cell membranes or bacterial membranes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K 35/407: Liver; Hepatocytes
- A61P 37/02: Immunomodulators
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 14/71: for growth factors; for growth regulators
- C12N 5/0656: {Adult fibroblasts}
- C12N 2500/90: Serum-free medium, which may still contain naturally-sourced components
- C12N 2501/33: Insulin
- C12N 2501/599: with CD designations not provided for elsewhere
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method of producing cell derived particles is disclosed. The method comprising isolating cell-derived particles from a biological sample comprising cells modified to present CD24 so as to obtain a preparation of the cell-derived particles substantially devoid of intact cells. Cell derived particles, a culture medium and a cell culture are also disclosed.

## Claims

### Claim 1

A method of treating a coronavirus infection in a subject in need thereof, the method comprising:
(a) isolating cell-derived particles from a biological sample comprising cells modified to present CD24 so as to obtain a preparation of the cell-derived particles substantially devoid of intact cells; and
(b) administering to the subject a therapeutically effective amount of the preparation of the cell-derived particles,
thereby treating the coronavirus infection in the subject.

### Claim 2 (depends on 1)

The method of claim 1, further comprising modifying cells to present CD24 to obtain said cells modified to present CD24 prior to said isolating cell-derived particles from a biological sample.

### Claim 3 (depends on 2)

The method of claim 2, further comprising culturing the cells modified to present CD24 prior to said isolating cell-derived particles from a biological sample.

### Claim 4 (depends on 3)

The method of claim 3, wherein the cells are cultured in a serum-free culture medium.

### Claim 5 (depends on 3)

The method of claim 3, wherein the cells are cultured in a suspension culture in the absence of insulin and albumin or wherein the cells are cultured in a 2D culture comprising insulin and albumin.

### Claim 6 (depends on 1)

The method of claim 1, wherein said CD24 is as set forth in SEQ ID NO: 9 or encodable by SEQ ID NO: 8.

### Claim 7 (depends on 1)

The method of claim 1, wherein said cell-derived particles are selected from the group consisting of exosomes, ARMM, microvesicles, exomeres, membrane particles, membrane vesicles and ectosomes.

### Claim 8 (depends on 1)

The method of claim 1, wherein said cell-derived particles have a mean particle diameter of about 80 to about 220 nm.

### Claim 9 (depends on 1)

The method of claim 1, wherein said cell-derived particles are exosomes.

### Claim 10 (depends on 1)

The method of claim 1, wherein said cells are cells of an animal or a human tissue.

### Claim 11 (depends on 1)

The method of claim 1, wherein said cells are genetically modified cells.

### Claim 12 (depends on 1)

The method of claim 1, wherein said cells are fibroblast cells or kidney cells.

### Claim 13 (depends on 1)

The method of claim 1, wherein said cells are human embryonic kidney 293 cells (HEK-293) cells.

### Claim 14 (depends on 1)

The method of claim 1, wherein said cells are human embryonic kidney 293 cells (HEK-293 cells) stably expressing the tetracycline repressor protein and genetically modified with a plasmid comprising CD24 gene cloned downstream to tetracycline-operator sequences and wherein said CD24 expression is inducible by tetracycline.

### Claim 15

A method of treating or preventing a cytokine storm syndrome in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition comprising exosomes presenting heterologous CD24 on their surface, wherein said exosomes are obtained from cells genetically modified to present said CD24, and wherein the composition is substantially devoid of intact cells, thereby treating or preventing the cytokine storm syndrome in the subject.

### Claim 16 (depends on 15)

The method of claim 15, wherein said CD24 is as set forth in SEQ ID NO: 9 or encodable by SEQ ID NO: 8.

### Claim 17 (depends on 15)

The method of claim 15, wherein said cells are fibroblast cells or kidney cells.

### Claim 18 (depends on 15)

The method of claim 15, wherein said cells are human embryonic kidney 293 cells (HEK-293) cells.

### Claim 19 (depends on 15)

The method of claim 15, wherein said therapeutically effective amount is 107-1012 exosomes per administration.

### Claim 20 (depends on 15)

The method of claim 15, wherein said heterologous CD24 is detected by ELISA, Western Blot or FACS.
